Wedbush Maintains Outperform on Foghorn Therapeutics, Raises Price Target to $20
Wedbush analyst Robert Driscoll maintains Foghorn Therapeutics (NASDAQ:FHTX) with a Outperform and raises the price target from $25 to $20.
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's session, 107 stocks hit new 52-week lows.
Morgan Stanley Maintains Equal-Weight on Foghorn Therapeutics, Lowers Price Target to $14
Morgan Stanley analyst Vikram Purohit maintains Foghorn Therapeutics (NASDAQ:FHTX) with a Equal-Weight and lowers the price target from $15 to $14.
